Search details
1.
DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
Blood
; 141(19): 2372-2389, 2023 05 11.
Article
in English
| MEDLINE | ID: mdl-36580665
2.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood
; 140(2): 112-120, 2022 07 14.
Article
in English
| MEDLINE | ID: mdl-35427411
3.
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Blood
; 139(24): 3519-3531, 2022 06 16.
Article
in English
| MEDLINE | ID: mdl-35192684
4.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Article
in English
| MEDLINE | ID: mdl-34407545
5.
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Blood
; 138(23): 2313-2326, 2021 12 09.
Article
in English
| MEDLINE | ID: mdl-34110416
6.
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
Br J Haematol
; 194(2): 309-318, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34145576
7.
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
Br J Haematol
; 191(1): 37-43, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32220069
8.
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Am J Hematol
; 94(1): 111-117, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30370956
9.
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
Acta Haematol
; 142(4): 224-232, 2019.
Article
in English
| MEDLINE | ID: mdl-31336367
10.
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.
Blood
; 127(12): 1551-8, 2016 Mar 24.
Article
in English
| MEDLINE | ID: mdl-26755712
11.
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.
Am J Hematol
; 93(8): 1074-1081, 2018 Aug.
Article
in English
| MEDLINE | ID: mdl-29905379
12.
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
Blood
; 123(11): 1665-73, 2014 Mar 13.
Article
in English
| MEDLINE | ID: mdl-24458437
13.
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.
Acta Haematol
; 136(4): 210-218, 2016.
Article
in English
| MEDLINE | ID: mdl-27632567
14.
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
Blood
; 117(20): 5306-13, 2011 May 19.
Article
in English
| MEDLINE | ID: mdl-21415269
15.
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
Blood
; 118(13): 3525-7, 2011 Sep 29.
Article
in English
| MEDLINE | ID: mdl-21803850
16.
Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia.
Cell Rep
; 42(7): 112804, 2023 07 25.
Article
in English
| MEDLINE | ID: mdl-37453060
17.
SINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
bioRxiv
; 2023 Dec 09.
Article
in English
| MEDLINE | ID: mdl-38106088
18.
Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 γδ T-ALL as an extremely high risk leukemia in the very young.
medRxiv
; 2023 Nov 08.
Article
in English
| MEDLINE | ID: mdl-37986997
19.
Anthracycline dose intensification in acute myeloid leukemia.
N Engl J Med
; 361(13): 1249-59, 2009 Sep 24.
Article
in English
| MEDLINE | ID: mdl-19776406
20.
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Blood
; 116(20): 4077-85, 2010 Nov 18.
Article
in English
| MEDLINE | ID: mdl-20716770